Skip to main content
Infuseon enters glioblastoma treatment partnership with OncoSynergy

A strategic alliance has been reached by Infuseon Therapeutics and OncoSynergy to establish proof of concept for the direct delivery of OncoSynergy's monoclonal pan-CD29 antibody OS2966 to the brain using Infuseon's Cleveland Multiport Catheter. The proof of concept will be used as a springboard to conduct a Phase I trial of the combined solutions for treating glioblastoma.

Full Story: